Imaging Partnerships Recent asset sale to Bayer highlights strong pharma interest in precision imaging for amyloidosis. This creates a sales opportunity to explore licensing or co-development of PAR-based diagnostic or radiotracer assets with large diagnostics and pharma players, leveraging Attralus' platform as a partner of choice in imaging-enabled therapies.

Regulatory Credibility Orphan Drug designation for AT-01 signals a viable regulatory path and a focused rare-disease opportunity. Use this as a lever to engage rare-disease centers, payers, and potential co-development partners on accelerated timelines and risk-sharing agreements.

Platform Synergy The pan-amyloid removal PAR approach offers cross-cutting collaboration potential—from additional amyloid targets to immunotherapy interfaces like CAR-M data—creating avenues for licensing, joint development, or platform expansion with biotech and academic partners.

Funding Momentum Recent financing reflects investor confidence and provides runway to advance programs, facilitating discussions with potential licensors, co-development partners, and trialists. Leverage this credibility in outreach to big pharma and CRO networks.

Clinical Network Active engagement with scientific conferences and institutional partners demonstrates a ready-made channel for site identification, investigator engagement, and patient recruitment in systemic amyloidosis, including connections with major hospitals and universities.